Events

2014 News Releases



Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
11/24/14Rigel Announces Executive Management Changes
James M. Gower Retires, Raul Rodriguez Named CEO and Appointed to the Board, Gary Lyons Named Chairman SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced James M. Gower is retiring from the board of directors and from his positions as chairman and chief executive officer, and Raul Rodriguez, most recently serving as the company's president and chief operating officer, will assume the position of chief executive officer and jo... 
Download PDFPrinter Friendly Version
11/04/14Rigel Announces Third Quarter 2014 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2014. For the third quarter of 2014, Rigel reported a net loss of $20.9 million, or $0.24 per share, compared to a net loss of $23.8 million, or $0.27 per share, for the same period of 2013. Weighted average shares outstanding for the third quarters of 2014 and 2013 were 87.8 million and 87.4 million, res... 
Download PDFPrinter Friendly Version
08/13/14R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study
Rigel Reiterates Clinical Focus on Fostamatinib for ITP and IgA Nephropathy SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease.  The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye sym... 
Download PDFPrinter Friendly Version
08/05/14Rigel Announces Second Quarter 2014 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014. For the second quarter of 2014, Rigel reported a net loss of $25.4 million, or $0.29 per share, compared to a net loss of $22.8 million, or $0.26 per share, in the same period of 2013. Weighted average shares outstanding for the second quarters of 2014 and 2013 were 87.5 million and 87.1 million, respect... 
Download PDFPrinter Friendly Version
07/16/14Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this autoimmune disease... 
Download PDFPrinter Friendly Version
05/29/14Rigel to Present at Jefferies 2014 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2014 Global Healthcare Conference in New York City on Tuesday, June 3rd at 2:30 p.m. ET. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to th... 
Download PDFPrinter Friendly Version
05/07/14Rigel Announces First Quarter 2014 Financial Results
SOUTH SAN FRANCISCO, Calif., May 7, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $25.6 million, or $0.29 per share, in the first quarter of 2013. Weighted average shares outstanding for the first quarters of 2014 and 2013 were 87.5 million and 87.1 million, respectively. Rigel ... 
Download PDFPrinter Friendly Version
04/30/14Rigel Announces Webcast of Investor Day on May 6, 2014
-- Company to Give Overview of Product Portfolio and Strategy -- SOUTH SAN FRANCISCO, Calif., April 30, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host an Investor Day on Tuesday, May 6, 2014 from 9:30 a.m. to 12:00 p.m. E.T. in New York City. Rigel management will provide an overview of the company's product portfolio and discuss future strategy. Donald G. Payan, M.D., executive vice president and president of discovery and research of ... 
Download PDFPrinter Friendly Version
03/06/14Rigel Announces Publication of R118 AMPK Activator Research
Initiates Phase 1 Trial for Intermittent Claudication SOUTH SAN FRANCISCO, Calif., March 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with its orally-bioavailable AMPK activator, R118.  The publication, entitled "Exercise performance and peripheral vascular insufficiency improve with AMPK activation…", provides strong preclinical evidence that R118 may be useful in t... 
Download PDFPrinter Friendly Version
03/04/14Rigel Announces Fourth Quarter and Year End 2013 Financial Results
SOUTH SAN FRANCISCO, Calif., March 4, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2013. For the fourth quarter of 2013, Rigel reported a net loss of $16.9 million, or $0.19 per share, compared to a net loss of $25.5 million, or $0.30 per share, in the fourth quarter of 2012. Weighted average shares outstanding for the fourth quarter of 2013 and 2012 were 87.4 million and 85.3 million, respe... 
Download PDFPrinter Friendly Version
02/27/14Rigel Announces Participation at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details of the events are as follows: Cowen and Company 34th Annual Health Care Conference Date – March 3, 2014 at 2:50 p.m. ET Location – Boston, MA Presenter – Ryan Maynard, Executive Vice President and Chief Financial Officer 26th Annual ROTH Conference Date – March 11, 2014 at 2:00 p.m. PT L... 
Download PDFPrinter Friendly Version
02/06/14Rigel Announces Participation at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at two investor conferences in New York City in February.  Details of the presentations are as follows: 16th Annual BIO CEO & Investor Conference Monday, February 10 at 2:00 p.m. ET RBC Capital Markets Global Healthcare Conference Tuesday, February 25 at 11:0... 
Download PDFPrinter Friendly Version
01/10/14Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
Earns $5.75M Milestone from AstraZeneca for Asthma Partnership SOUTH SAN FRANCISCO, Calif., Jan. 10, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present updated product development plans and a financial update at the upcoming 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16th at 9:00 a.m. PT (see webcast details below).  Information will be ... 
Download PDFPrinter Friendly Version